The first FDA cleared medical device for the capture and harvest of circulating tumor cells (CTCs) from metastatic breast cancer (MBC) patient blood for subsequent analysis
The Parsortix® PC1 Clinical System is a next generation liquid biopsy technology. Starting from a simple blood draw, which is non-invasive and can be repeated as often as needed, the system enriches to provide intact cancer cells, providing a real-time sample for subsequent analyses by common laboratory techniques*, enabling a complete picture of the cancer.
Unlike ctDNA, which is limited to DNA analysis and is the focus for most of the liquid biopsy industry, a full range of analyses can be undertaken with CTCs, giving a potential alternative to a tissue biopsy.
Benefits of Parsortix® technology
CTCs are captured based on their size and deformability, enabling the isolation of live epithelial and mesenchymal CTCs and CTC clusters for subsequent analysis including:
- Cytological examination
- DNA, RNA and protein analyses
- Single cell picking and analyses
The ability to monitor and analyze CTCs may transform the treatment of MBC, providing patients with personalized cancer care through a non-invasive, repeat liquid biopsy with the power of Parsortix® technology.